NeuroBo says DA-1241, Wegovy combo shows potential in treating MASH

seekingalpha05-22

NeuroBo Pharmaceuticals (NASDAQ:NRBO) said that preclinical data indicates that its drug candidate DA-1241 in combination Wegovy was able to improve liver fibrosis in patients with metabolic ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2437296759?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1465361950/image_1465361950.jpg","is_english":true,"pubTime":"2024-05-22 22:01","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2437296759","market":"nz","top_or_hot":-1,"title":"NeuroBo says DA-1241, Wegovy combo shows potential in treating MASH","media":"seekingalpha","content":"<div>\n<p>NeuroBo Pharmaceuticals (NASDAQ:NRBO) said that preclinical data indicates that its drug candidate DA-1241 in combination Wegovy was able to improve liver fibrosis in patients with metabolic ...</p>\n\n<a href=\"https://seekingalpha.com/news/4109331-neurobo-says-da-1241-wegovy-combo-shows-potential-in-treating-mash\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeuroBo says DA-1241, Wegovy combo shows potential in treating MASH</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuroBo says DA-1241, Wegovy combo shows potential in treating MASH\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-22 22:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4109331-neurobo-says-da-1241-wegovy-combo-shows-potential-in-treating-mash><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NeuroBo Pharmaceuticals (NASDAQ:NRBO) said that preclinical data indicates that its drug candidate DA-1241 in combination Wegovy was able to improve liver fibrosis in patients with metabolic ...</p>\n\n<a href=\"https://seekingalpha.com/news/4109331-neurobo-says-da-1241-wegovy-combo-shows-potential-in-treating-mash\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://seekingalpha.com/news/4109331-neurobo-says-da-1241-wegovy-combo-shows-potential-in-treating-mash","article_id":"2437296759","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1465361950/image_1465361950.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2437296759","pubTimestamp":1716386466,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"NeuroBo Pharmaceuticals  said that preclinical data indicates that its drug candidate DA-1241 in combination Wegovy was able to improve liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis, or MASH. The study also suggested the combination demonstrated additive hepatoprotective effects in preclinical MASH models, NeuroBo said in a statement. Researchers intend to present the data on June 6 at the European Association for the Study of the Liver meeting, to be held in Milan from June 5 to 8. Topline data from an ongoing Phase 2a study of the product in treating MASH is expected in Q4. Wegovy, also known as semaglutide, is marketed by Novo Nordisk . Semaglutide is also sold for the treatment of diabetes under the brand name Ozempic.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德","NRBO":"NeuroBo Pharmaceuticals, Inc.","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","BK4007":"制药","BK4532":"文艺复兴科技持仓"},"translate_title":"NeuroBo说DA-1241，Wegovy组合显示出处理糖化醪的潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRBO":1,"NVO":1},"content_text":"NeuroBo Pharmaceuticals (NASDAQ:NRBO) said that preclinical data indicates that its drug candidate DA-1241 in combination Wegovy was able to improve liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis, or MASH. The study also suggested the combination demonstrated additive hepatoprotective effects in preclinical MASH models, NeuroBo said in a statement. Researchers intend to present the data on June 6 at the European Association for the Study of the Liver meeting, to be held in Milan from June 5 to 8. Topline data from an ongoing Phase 2a study of the product in treating MASH is expected in Q4. Wegovy, also known as semaglutide, is marketed by Novo Nordisk (NVO). Semaglutide is also sold for the treatment of diabetes under the brand name Ozempic.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2437296759"}